High-throughput screening to enhance oncolytic virus immunotherapy
Authors:
Open Access
- 1 April 2016
- journal article
- review article
- Published by Taylor & Francis in Oncolytic Virotherapy
- Vol. ume 5, 15-25
Abstract
High-throughput screening to enhance oncolytic virus immunotherapy KJ Allan,1,2 David F Stojdl,1–3 SL Swift1 1Children’s Hospital of Eastern Ontario (CHEO) Research Institute, 2Department of Biology, Microbiology and Immunology, 3Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada High-throughput screens can rapidly scan and capture large amounts of information across multiple biological parameters. Although many screens have been designed to uncover potential new therapeutic targets capable of crippling viruses that cause disease, there have been relatively few directed at improving the efficacy of viruses that are used to treat disease. Oncolytic viruses (OVs) are biotherapeutic agents with an inherent specificity for treating malignant disease. Certain OV platforms – including those based on herpes simplex virus, reovirus, and vaccinia virus – have shown success against solid tumors in advanced clinical trials. Yet, many of these OVs have only undergone minimal engineering to solidify tumor specificity, with few extra modifications to manipulate additional factors. Several aspects of the interaction between an OV and a tumor-bearing host have clear value as targets to improve therapeutic outcomes. At the virus level, these include delivery to the tumor, infectivity, productivity, oncolysis, bystander killing, spread, and persistence. At the host level, these include engaging the immune system and manipulating the tumor microenvironment. Here, we review the chemical- and genome-based high-throughput screens that have been performed to manipulate such parameters during OV infection and analyze their impact on therapeutic efficacy. We further explore emerging themes that represent key areas of focus for future research. Keywords: oncolytic, virus, screen, high-throughput, cancer, chemical, genomic, immunotherapyKeywords
This publication has 66 references indexed in Scilit:
- Oncolytic viruses: a new class of immunotherapy drugsNature Reviews Drug Discovery, 2015
- High-throughput functional genomics using CRISPR–Cas9Nature Reviews Genetics, 2015
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade ImmunotherapyScience Translational Medicine, 2014
- Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment StrategiesMolecular Therapy, 2014
- Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic EfficacyCancer Immunology Research, 2013
- Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+T-cell responses to anticancer vaccinesOncoImmunology, 2013
- An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor ClearanceMolecular Therapy, 2012
- Targeting a cornerstone of radiation resistance: Cancer stem cellCancer Letters, 2012
- Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by RapamycinCancer Research, 2007
- Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesisOncogene, 1999